These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?]. Netti GS; Ranieri E G Ital Nefrol; 2014; 31(3):. PubMed ID: 25030016 [TBL] [Abstract][Full Text] [Related]
3. [Preliminary results of research on a new marker of idiopathic membranous nephropathy: anti-PLA2R]. Kozioł M; Sikora A; Kozioł-Montewka M; Smarz-Widelska I; Orłowska-Kowalik G; Pyszna W; Załuska W; Ksiazek A Pol Merkur Lekarski; 2014 Mar; 36(213):171-4. PubMed ID: 24779214 [TBL] [Abstract][Full Text] [Related]
4. [Membranous glomerulonephritis: better therapy with autoantibody monitoring?]. Stahl RA; Hoxha E; Helmchen U Dtsch Med Wochenschr; 2011 Aug; 136(34-35):1733-7. PubMed ID: 21877306 [TBL] [Abstract][Full Text] [Related]
5. Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report. Al-Rabadi L; Ayalon R; Bonegio RG; Ballard JE; Fujii AM; Henderson JM; Salant DJ; Beck LH Am J Kidney Dis; 2016 May; 67(5):775-8. PubMed ID: 26744127 [TBL] [Abstract][Full Text] [Related]
6. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy. Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases. Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027 [TBL] [Abstract][Full Text] [Related]
8. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. Cravedi P; Ruggenenti P; Remuzzi G J Am Soc Nephrol; 2011 Aug; 22(8):1400-2. PubMed ID: 21784892 [No Abstract] [Full Text] [Related]
14. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Svobodova B; Honsova E; Ronco P; Tesar V; Debiec H Nephrol Dial Transplant; 2013 Jul; 28(7):1839-44. PubMed ID: 23223223 [TBL] [Abstract][Full Text] [Related]
15. Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. Timmermans SA; Ayalon R; van Paassen P; Beck LH; van Rie H; Wirtz JJ; Verseput GH; Frenken LA; Salant DJ; Cohen Tervaert JW; Am J Kidney Dis; 2013 Dec; 62(6):1223-5. PubMed ID: 24021909 [No Abstract] [Full Text] [Related]
16. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Dähnrich C; Komorowski L; Probst C; Seitz-Polski B; Esnault V; Wetzels JF; Hofstra JM; Hoxha E; Stahl RA; Lambeau G; Stöcker W; Schlumberger W Clin Chim Acta; 2013 Jun; 421():213-8. PubMed ID: 23541686 [TBL] [Abstract][Full Text] [Related]
17. PLA2R and membranous nephropathy: A 3 year prospective Australian study. Hill PA; McRae JL; Dwyer KM Nephrology (Carlton); 2016 May; 21(5):397-403. PubMed ID: 26369693 [TBL] [Abstract][Full Text] [Related]
18. Nephrotic syndrome: A new specific test for idiopathic membranous nephropathy. Debiec H; Ronco P Nat Rev Nephrol; 2011 Aug; 7(9):496-8. PubMed ID: 21826078 [No Abstract] [Full Text] [Related]
19. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. Debiec H; Ronco P N Engl J Med; 2011 Feb; 364(7):689-90. PubMed ID: 21323563 [No Abstract] [Full Text] [Related]
20. Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens. Medrano AS; Escalante EJ; Cáceres CC; Pamplona IA; Allende MT; Terrades NR; Carmeno NV; Roldán EO; Agudelo KV; Vasquez JJ Biomarkers; 2015 Feb; 20(1):77-83. PubMed ID: 25519165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]